Skip to main content
Premium Trial:

Request an Annual Quote

Cytoclonal Launches Oasis Genome Library for Gene-Based Pharmaceuticals

Premium

D

ALLAS--Cytoclonal Pharmaceutics announced that it has launched a genome library of commercial reagents called Oasis that has the ability to regulate genes being uncovered by the Human Genome Project. Oasis, developed together with the University of Texas here, regulates genes using the company’s patented optimum antisense reagents. Cytoclonal’s other main platform is its Quantum Core Technology, a drug design technology that targets proteins involved in disease. "The combination of the Oasis genome library and the QCT drug design technology allows Cytoclonal to develop drugs based on gene and protein data," said Arthur Bollon, the company’s chairman and CEO. Cytoclonal plans to develop new compounds internally and license some of them to other companies.

Filed under

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.